Biopharma Deal
Benchmarks 2026
Upfront ranges, milestone structures, royalty benchmarks, and deal-flow trends across all 12 therapeutic areas — sourced from 2,700+ verified transactions in the Ambrosia Benchmarker corpus.
Download the report
Free — enter your email and it's yours.
No spam. Report delivered instantly. Unsubscribe anytime.
The comp set your committee needs.
Every section is anchored to verified closed transactions — not estimates, not models, not survey data.
Upfront Benchmarks by Phase
Median upfront ranges for preclinical through approved, broken out by modality and therapeutic area. See exactly where the market prices each stage.
9 phases × 12 TAsDeal Flow Trends
Quarter-over-quarter transaction volume, average deal sizes, and the TAs seeing the most activity. Spot where capital is concentrating.
500+ deals trackedTop Acquirers & Partners
Which pharma companies are doing the most deals, what they're paying, and which modalities they're targeting. Counterparty intelligence for your pitch.
1,308 companies profiledSample findings from the report
A preview of the intelligence inside.
Enter your email above to unlock.
Get deal intelligence in your inbox
Weekly benchmarks, market signals, and deal analysis from 1,900+ transactions.
No spam. Unsubscribe anytime.
Report data sourced from the Ambrosia Benchmarker deal intelligence platform — 2,700+ verified biopharma transactions, 1,308 company profiles, 14 valuation engines. Updated weekly from SEC EDGAR, ClinicalTrials.gov, press disclosures, and proprietary calibration corpus.